Related Experiment Video
Updated: Jul 14, 2026
09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
Exenatide blocks JAK1-STAT1 in pancreatic beta cells
Francesca M Couto1, Alexandra H Minn, Cynthia A Pise-Masison
1Department of Medicine, University of Wisconsin, Madison, WI, USA.
Metabolism: Clinical and Experimental
|June 16, 2007
Summary
Exenatide (Ex-4) may protect against type 1 diabetes by down-regulating the JAK1-STAT1 pathway in human islets. This finding suggests Ex-4 could prevent cytokine-induced beta cell death.
Area of Science:
- Endocrinology
- Molecular Biology
- Diabetes Research
Background:
- Exenatide (Ex-4) is a glucagon-like peptide 1 receptor agonist approved for type 2 diabetes.
- Ex-4 demonstrates potential in rodent models of type 1 diabetes by affecting beta cell gene expression and mass.
- The precise mechanisms underlying Ex-4's effects on beta cells, particularly in type 1 diabetes, remain unclear.
Purpose of the Study:
- To investigate the molecular pathways modulated by Exenatide (Ex-4) in human pancreatic islets.
- To identify novel targets of Ex-4 relevant to beta cell function and survival.
Main Methods:
- Oligonucleotide microarrays were employed to analyze gene expression changes induced by Ex-4 in human islets.
- Pathway analysis was performed using PathwayStudio software to identify affected signaling cascades.
- Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) was utilized to validate key gene expression findings in human islets and INS-1 cells.
Main Results:
- The Janus kinase 1-Signal transducer and activator of transcription 1 (JAK1-STAT1) pathway was identified as a novel target of Ex-4.
- Ex-4 treatment led to the down-regulation of JAK1 and STAT1 gene expression in human islets and INS-1 cells.
- The JAK1-STAT1 pathway is critically involved in mediating interferon gamma-induced beta cell apoptosis in type 1 diabetes.
Conclusions:
- Exenatide (Ex-4) modulates the JAK1-STAT1 signaling pathway in human pancreatic islets.
- Inhibition of the JAK1-STAT1 pathway by Ex-4 may offer a protective mechanism against cytokine-induced beta cell death.
- These findings suggest a potential therapeutic role for Ex-4 in managing type 1 diabetes by preserving beta cell function and viability.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...